Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Imodium Syrup Versus Imodium Tablets for Faecal Incontinence

This study has been withdrawn prior to enrollment.
Sponsor:
Collaborator:
University of Southampton
Information provided by:
University Hospital Southampton NHS Foundation Trust.
ClinicalTrials.gov Identifier:
NCT00933465
First received: July 3, 2009
Last updated: November 17, 2014
Last verified: November 2014

July 3, 2009
November 17, 2014
October 2009
May 2010   (final data collection date for primary outcome measure)
To evaluate the use of imodium as tablets or syrup in the treatment of faecal incontinence in order to improve the scores of patients with faecal incontinence as seen with continence and quality of life questionnaires [ Time Frame: 2 sets of 6 weeks (3 months) ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00933465 on ClinicalTrials.gov Archive Site
  • To reduce to number of patients suffering from faecal incontinence [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Number of episodes of total, urge and passive incontinence [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Total number of patient incontinent days [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Use of pads and other medications [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Ability to defer defaecation [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Adverse effects relating to medication [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
  • Determining the direct medical costs, direct non-medical costs, indirect non-medical costs associated with the treatment of Faecal incontinence, and cost effectiveness of treatment with syrup and tablets [ Time Frame: 3 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Imodium Syrup Versus Imodium Tablets for Faecal Incontinence
Single Blinded Randomised Cross-over Study of Imodium Tablets Versus Imodium Syrup for the Treatment of Faecal Incontinence

Faecal incontinence (FI) is a debilitating and often neglected problem. It can be defined as the loss of voluntary control of liquid or solid stool.It is estimated that 2-3% of western adults suffer from FI with prevalence increasing with age, further to this up to 50% of nursing home residents suffer too with it more common in females. Aetiology is often multi-factoral, where obstetric anal sphincter injury is most common is females and iatrogenic anal sphincter injury is most common in males.

Loperamide (imodium) is a constipating agent used as first choice pharmacological agent due to its high efficacy. Trials have suggested it thickens stool consistency and may raise resting anal sphincter pressure, associated with improved clinical function with a reduction in bowel frequency and urgency, a reduction in incontinence and less need for pads.

Loperamide is well tolerated but has been known to cause side effects of abdominal pain and distension, nausea and vomiting and constipation.

Imodium can be taken in two ways; as syrup (1mg/5mls) or tablets (2mg). There have been no comparative studies. Side effects are mainly seen with the tablet form and so it is hypothesized that the syrup form is better tolerated because it is more accurately titrated to effect.

This is a NHS funded single blinded, randomised, cross-over study to assess the clinical effects of Imodium, in tablet and syrup form, on patients presenting with faecal incontinence. Each subject will act as their own control. Patients will be recruited through out-patient visits for their FI, where they will be made aware of the trial. During the trial they will be asked to fill out FI scoring questionnaires and quality of life scores. Also they will undertake two assessments of anal physiology testing squeeze pressures, sensation and compliance at baseline and at the end after three months.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Fecal Incontinence
  • Drug: Imodium (Loperamide Hydrochloride) syrup

    syrup (orally), max dose per day; 16x 5ml spoonfuls (80ml) Titrated from low dose to clinically relevant dose as described by the patient and their symptoms.

    Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most.

  • Drug: Imodium (Loperamide hydrochloride) tablets

    tablets (orally) max dose per day; in chronic diarrhea, 8 capsules (16 mg) titrated from low dose to clinically relevant dose as described by patient and their symptoms.

    Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most

  • Experimental: tablets first followed by syrup
    first 6 weeks of study using tablets, then followed by assessment, and then the next 6 weeks using syrup, followed by assessment
    Interventions:
    • Drug: Imodium (Loperamide Hydrochloride) syrup
    • Drug: Imodium (Loperamide hydrochloride) tablets
  • Experimental: Syrup first followed by tablets
    first 6 weeks of study using syrup, then followed by assessment, and then the next 6 weeks using tablets, followed by assessment
    Interventions:
    • Drug: Imodium (Loperamide Hydrochloride) syrup
    • Drug: Imodium (Loperamide hydrochloride) tablets

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
May 2010
May 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Aged 18 - 75
  • Severe faecal incontinence defined as greater than one episode per week of involuntary loss of either solid or liquid stool as demonstrated by means of a baseline bowel habit and a Vaizey score of greater than 4.
  • Competent and willing to fill in questionnaires and attend follow up clinics through out the study period.

Exclusion Criteria:

  • Alternating bowel habit, associated with symptoms of constipation. Use of other regular or as required medications that may affect bowel function. (e.g. codeine phosphate).
  • Patients with complete or partial spinal cord injuries including cauda equina syndrome.
  • Active inflammatory bowel disease.
  • Pregnancy
  • Stoma in situ
  • Psychiatric and physiological inability to comply with study protocol.
  • Non english speakers (student project funding cannot cover interpreter and other costs)

(application of criteria at the discretion of the investigating doctor at initial consultation)

Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT00933465
RHMMED0874, eudraCT number; 2009-013776-49
No
Miss Karen Nugent, Southampton University hospital NHS trust
University Hospital Southampton NHS Foundation Trust.
University of Southampton
Principal Investigator: Karen Nugent, MA MSmedFRCS University Hospital Southampton NHS Foundation Trust.
University Hospital Southampton NHS Foundation Trust.
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP